Announced details
Nonclinical CRO business, NHP testing, and development of next-generation pharmaceuticals, including nucleic acid therapeutics and gene therapy products
The counterparty to the site location agreement concerning the construction of a new facility within the grounds of the Kagoshima headquarters. No capital or personal relationship is disclosed.
Kagoshima City, Kagoshima Prefecture. The mayor of Kagoshima City is Shimotsuru Takao (下鶴隆央).
2643 Miyanoura-cho, Kagoshima City, Kagoshima Prefecture (within the grounds of the Kagoshima headquarters)
The company expects orders to expand further going forward and anticipates contributing to job creation and regional revitalization. The specific impact on operating results is not disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | NHP Testing Facility, EU Experimental Building; NHP testing using large animal housing cages compliant with EU standards |
| Counterparty | Kagoshima City |
| Counterparty overview | Kagoshima City, Kagoshima Prefecture. The mayor of Kagoshima City is Shimotsuru Takao (下鶴隆央). |
| Relationship with the Company | The counterparty to the site location agreement concerning the construction of a new facility within the grounds of the Kagoshima headquarters. No capital or personal relationship is disclosed. |
| Contract Date | 30 March 2026 |
| Launch date | November 2027 (scheduled; facility commencement of operations) |
| Applicable area | Nonclinical CRO business, NHP testing, and development of next-generation pharmaceuticals, including nucleic acid therapeutics and gene therapy products |
| Location | 2643 Miyanoura-cho, Kagoshima City, Kagoshima Prefecture (within the grounds of the Kagoshima headquarters) |
| Location scale | Building area: 11,765.18 m²; four-story above-ground reinforced-concrete building |
| Impact on Business Performance | The company expects orders to expand further going forward and anticipates contributing to job creation and regional revitalization. The specific impact on operating results is not disclosed. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To capture additional orders from European and U.S. customers and support NHP testing using large animal housing cages compliant with EU standards. Against a backdrop of sharply increasing demand for nonclinical testing of next-generation pharmaceuticals, including nucleic acid therapeutics and gene therapy products, as well as the execution of preferred vendor agreements with major European and U.S. pharmaceutical companies, the company expects orders to expand going forward.